Fluacrypyrim, a novel STAT3 activation inhibitor, induces cell cycle arrest and apoptosis in cancer cells harboring constitutively‐active STAT3
Open Access
- 19 July 2010
- journal article
- carcinogenesis
- Published by Wiley in International Journal of Cancer
- Vol. 127 (6), 1259-1270
- https://doi.org/10.1002/ijc.25169
Abstract
STAT3 protein has an important role in oncogenesis and is a promising anticancer target. Herein, we demonstrate that a novel small molecule fluacrypyrim (FAPM) inhibits the growth of leukemia cells by a predominant G1 arrest with significant decrease of the protein and mRNA levels of cyclin D1. As cyclin D1 is transcriptionally regulated by STAT3, FAPM is then shown to markedly inhibit the STAT3 phosphorylation with marginal effect on the other signal transducers and activators of transcription, and without effect on phosphoinositide‐3‐kinase and mitogen‐activated protein kinase pathways. Further analysis shows that FAPM significantly increases the protein tyrosine phosphatases (PTPs) activity in a dose‐dependent manner, and the inhibition of PTP activation by sodium pervanadate reverses FAPM‐induced suppression of STAT3 tyrosine phosphorylation, indicating an important role of PTP in the action of FAPM. Finally, FAPM treatment results in selective suppression of STAT3‐mediated transcriptional activity and its downstream effectors, and subsequent induction of growth arrest and apoptosis in STAT3‐dependent cancer cell lines. This study therefore identifies FAPM as a potent STAT3 activation inhibitor with possible therapeutic potential against malignancies with constitutive STAT3 activation.Keywords
This publication has 50 references indexed in Scilit:
- Melissoidesin G, a diterpenoid purified from Isodon melissoides, induces leukemic‐cell apoptosis through induction of redox imbalance and exhibits synergy with other anticancer agentsInternational Journal of Cancer, 2007
- Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activityProceedings of the National Academy of Sciences of the United States of America, 2007
- Tyk2 Tyrosine Kinase Expression Is Required for the Maintenance of Mitochondrial Respiration in Primary Pro-B LymphocytesMolecular and Cellular Biology, 2006
- Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancerMolecular Cancer Therapeutics, 2006
- Down-Regulation of Signal Transducer and Activator of Transcription 3 Expression Using Vector-Based Small Interfering RNAs Suppresses Growth of Human Prostate Tumor In vivoClinical Cancer Research, 2005
- The STATs of cancer — new molecular targets come of ageNature Reviews Cancer, 2004
- Constitutive activation of STAT transcription factors in acute myelogenous leukemiaEuropean Journal of Haematology, 2001
- STAT proteins: novel molecular targets for cancer drug discoveryOncogene, 2000
- STAT signaling in the pathogenesis and treatment of leukemiasOncogene, 2000
- Stat3: a STAT Family Member Activated by Tyrosine Phosphorylation in Response to Epidermal Growth Factor and Interleukin-6Science, 1994